Proteomics International Laboratories Ltd

ASX:PIQ ISIN:AU000000PIQ0

Proteomics International Laboratories LtdProteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical technology company at the forefront of predictive diagnostics and bioanalytical services. The Company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

 
 
   

View in Other Languages

News

Proteomics International Laboratories Ltd (ASX:PIQ) Quarterly Activities/Appendix 4C Cash Flow Report

🕔7/28/2025 8:43:33 AM 551

Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics and precision medicine, is pleased to provide the following update on its business activities for the three months to 30 June 2025 and subsequent to the period end.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Next-Gen PromarkerD Test Performance Results Published

🕔7/24/2025 1:32:02 PM 1387

Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce the publication of results demonstrating the accuracy and performance of its next-generation PromarkerD test system.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) OxiDx Test Detects Muscle Damage in Thoroughbred Racehorses

🕔7/14/2025 8:19:36 AM 1368

Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce that in collaboration with The University of Western Australia, groundbreaking results demonstrate that the test for oxidative stress can identify muscle damage in Australian thoroughbred racehorses.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) AMA Grants Reimbursement Code for Next-Gen PromarkerD Test

🕔7/3/2025 8:20:50 AM 1674

Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce the assignment of billing code (0579U) by the American Medical Association (AMA) for the next-generation of the PromarkerD test system.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Funding Boost for Precision Diagnostics Proteomics Facility

🕔7/1/2025 8:30:25 AM 1604

Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce a major $6 million expansion of the WA Proteomics Facility, in partnership with The University of Western Australia (UWA), the WA State Government and Bioplatforms Australia.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) First Patent for Endometriosis Blood Test - Granted in Japan

🕔6/30/2025 8:24:12 AM 1579

Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce that the Japan Patent Office has granted the Company its first patent for PromarkerEndo, the proprietary diagnostic blood test for endometriosis.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Next-gen PromarkerD test system released for predicting Diabetic Kidney Disease

🕔6/23/2025 8:19:55 AM 2621

Proteomics International Laboratories Ltd (ASX:PIQ) Next-gen PromarkerD test system released for predicting DKD

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) PromarkerD Launched into the US at Major Diabetes Conference

🕔6/20/2025 8:36:42 AM 1878

Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, proudly announces the initial US launch of its groundbreaking predictive test for diabetic kidney disease, PromarkerD, at the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) A Landmark in Non-Invasive Esophageal Cancer Diagnosis

🕔6/5/2025 9:22:12 AM 2108

Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics is pleased to announce the publication of clinical validation results in the journal Proteomes showing its PromarkerEso blood test can diagnose esophageal adenocarcinoma with high accuracy.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) New Blood Test For Endometriosis Moves Closer to Market

🕔5/30/2025 12:34:20 PM 2021

Proteomics International Laboratories Ltd (ASX:PIQ) has unveiled landmark clinical data confirming its Promarker(R)Endo blood test as a highly accurate, non-invasive diagnostic tool for endometriosis.

Read Full Article
###

33,862 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 427) (Last 30 Days: 1206) (Since Published: 24475) 

Company Data

    Headquarters
  • QEII Medical Centre
    6 Verdun Street
    Nedlands WA 6009
    Australia
  • Telephone
  • +61-8-9389-1992 
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.proteomics.com.au